News

Higher Medicine Announces Strategic Investment by Cerdwen to Accelerate Therapies for Kabuki Syndrome and Other Brain Disorders

Higher Medicine Inc.  announced a strategic investment and fundraising partnership with Cerdwen, a venture capital firm focused on health and performance technology innovation.

Based in West Chester, Pennsylvania, Cerdwen partners with visionary founders to advance transformative healthcare technologies, supporting the translation of bold scientific ideas into meaningful clinical and commercial impact.

“Higher Medicine exemplifies the type of company we seek to partner with: rigorous science, a focused initial indication, and a platform capable of expanding into significant unmet medical needs,” said Kevin Brophy, Managing Principal of Cerdwen. “Dr. Kim and his team are tackling complex CNS disorders with a differentiated epigenetic approach, and we believe the company is well-positioned to translate that ambition into clinical impact.”

“Higher Medicine was founded on a simple but ambitious belief: that many devastating brain disorders need not be lifelong sentences,” said Dr. Leo Kim, Founder and CEO of Higher Medicine. “By harnessing epigenetic biology, we aim to prevent, slow, or even reverse conditions that few companies are willing to confront. Our initial focus on Kabuki syndrome is a deliberate entry point into a broader platform that can be extended to multiple high-unmet-need CNS indications such as CTE and Alzheimer’s disease. With Cerdwen’s investment, we will heighten the momentum for the seed round and accelerate toward clinical proof-of-concept.”

“This investment represents a strong validation of Higher Medicine’s scientific vision and execution,” said Marie Mazur, Board Member of the Mid-Atlantic Diamond Venture (MADV). “It also highlights the power of MADV’s regional biotech network and quarterly Forums, as this partnership originated from our December pitch event.”

The investment was completed via a Simple Agreement for Future Equity (SAFE) and closed on December 31, 2025. The transaction advances Higher Medicine’s Seed Expansion financing and marks a key milestone toward first-in-human clinical studies.

Read more here.

Recent News

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …

11/04/2026

$6 Million in Philanthropic Gifts Establishes UVA Biotech Innovation Fund

The University of Virginia Paul and Diane Manning Institute of Biotechnology received gifts totaling $6 million from philanthropists to establish the UVA Biotech Innovation Fund. This fund will provide long-term support for the UVA SPARK Innovative Medicines program, helping accelerate promising discoveries toward new treatments and cures. “The mission of the UVA Manning Institute of …

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …